Company profile: Senda Biosciences
1.1 - Company Overview
Company description
- Provider of a therapeutics platform leveraging insights into molecular connections between humans, offering Endless RNA (eRNA) to program proteins inside the body with long-lasting expression, Natural NanoParticle (NNP) technology with nanoparticles derived from nature for targeted delivery of biomolecules into human cells, and AI-driven integrative design of RNA medicines for oncology and rare diseases.
Products and services
- AI-driven integrative design of RNA medicines: AI-driven algorithms architect RNA medicines targeting various diseases, including oncology and rare diseases
- Endless RNA (eRNA): A synthetic, stable RNA technology that programs diverse proteins inside the body, achieving long-lasting expression
- Natural NanoParticle (NNP) deployment technology: Proprietary nanoparticles derived from nature deliver biomolecules into human cells with targeted specificity for intracellular uptake
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Senda Biosciences
Anji Pharma
HQ: United States
Website
- Description: Provider of therapeutics targeting high-value, human genetics-validated targets, including ANJ900, a gut-targeted formulation of metformin for type 2 diabetes patients with advanced chronic kidney disease to lower glucose with reduced systemic exposure, and ANJ908 (Pradigastat), a DGAT1 inhibitor for chronic idiopathic constipation to increase bowel movement frequency and soften stool.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anji Pharma company profile →
Covagen
HQ: Switzerland
Website
- Description: Provider of bispecific FynomAbs by fusing human Fynomer binding proteins to antibodies, creating protein-based therapeutics with novel modes of action and enhanced efficacy for the treatment of inflammatory diseases and cancer; ability to fuse Fynomers to multiple antibody sites enables tailored architectures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Covagen company profile →
Idorsia
HQ: Switzerland
Website
- Description: Provider of innovative biopharmaceutical therapies and resources, including daridorexant (QUVIVIQ), a dual orexin receptor antagonist for chronic insomnia, aprocitentan (TRYVIO/JERAYGO), an oral dual endothelin receptor antagonist for resistant hypertension, and a medical information and educational portal for healthcare professionals and patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idorsia company profile →
Medarex
HQ: United States
Website
- Description: Provider of fully human antibody-based therapeutics, focused on discovering, developing and commercializing treatments for life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases, leveraging its UltiMAb technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medarex company profile →
PepGen
HQ: United Kingdom
Website
- Description: Provider of an Enhanced Delivery Oligonucleotide (EDO) platform to improve delivery and efficacy of oligonucleotide therapies, focusing on antisense oligonucleotides for neuromuscular and neurological disorders, and therapy candidates including PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) and PGN-EDO51 for Duchenne Muscular Dystrophy (DMD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PepGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Senda Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Senda Biosciences
2.2 - Growth funds investing in similar companies to Senda Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Senda Biosciences
4.2 - Public trading comparable groups for Senda Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →